Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash from Financing Activities: 2020-2023

Historic Cash from Financing Activities for Cullinan Therapeutics (CGEM) over the last 4 years, with Dec 2023 value amounting to $248,000.

  • Cullinan Therapeutics' Cash from Financing Activities rose 100.75% to $248,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $40.8 million, marking a year-over-year increase of 257.14%. This contributed to the annual value of $266.2 million for FY2024, which is 553.21% up from last year.
  • According to the latest figures from Q4 2023, Cullinan Therapeutics' Cash from Financing Activities is $248,000, which was up 121.43% from $112,000 recorded in Q3 2023.
  • Cullinan Therapeutics' 5-year Cash from Financing Activities high stood at $264.6 million for Q1 2021, and its period low was -$32.9 million during Q4 2022.
  • In the last 3 years, Cullinan Therapeutics' Cash from Financing Activities had a median value of $1.6 million in 2022 and averaged $23.6 million.
  • In the last 5 years, Cullinan Therapeutics' Cash from Financing Activities crashed by 1,318.06% in 2022 and then spiked by 1,817.64% in 2023.
  • Cullinan Therapeutics' Cash from Financing Activities (Quarterly) stood at $124.9 million in 2020, then plummeted by 97.84% to $2.7 million in 2021, then slumped by 1,318.06% to -$32.9 million in 2022, then surged by 100.75% to $248,000 in 2023.
  • Its Cash from Financing Activities stands at $248,000 for Q4 2023, versus $112,000 for Q3 2023 and $38.6 million for Q2 2023.